JAPAN NICHE LENSRESEARCH NOTE 01 / 24 AUG 2026Back to research index

SCIENTIFIC INSTRUMENTS / NMR / JAPAN LENS

JEOL vs Bruker

What a Japanese lab sees that financial screens miss

In NMR, hardware is only the visible layer. Training, software, probes, service, sample workflows and years of comparable data create the real switching cost.

12 MIN READENGLISH / 日本語要約
TSE:6951JEOLTokyo
NASDAQ:BRKRBrukerBillerica

01 / THE FIVE-LINE ANSWER

This is not a clean two-company horse race.

Bruker has the clearer position at the ultra-high-field end of NMR. JEOL remains a credible alternative with a dense Japanese support base and a broader life-science strategy spanning electron microscopy, MicroED, mass spectrometry and NMR. But neither listed company is a pure NMR exposure.

  1. 01

    Bruker leads the visible high-field frontier. Its current portfolio extends through GHz-class systems, while its 2025 annual report records two 1.2 GHz installations.57

  2. 02

    JEOL competes as a platform, not a discount box. Its ECZ Luminous architecture and Delta software sit inside a broader analytical-instrument portfolio.3

  3. 03

    The installed base is made of local islands. Osaka University shows a Bruker cluster, RIKEN shows a JEOL cluster, and Kyoto University lists both vendors.91011

  4. 04

    The stocks are more diversified than the lab debate. JEOL’s segment includes microscopy and other analytical tools; Bruker BioSpin includes magnetic resonance, preclinical imaging, automation, services and data.

  5. 05

    An exact “80/20” market-share story does not pass our evidence test. The primary disclosures reviewed do not provide a comparable NMR-only share figure, so this note does not invent one.

EDITORIAL RULE

Institutional equipment lists demonstrate presence and workflow entrenchment. They do not establish national or global market share.

02 / FINANCIAL FRAME

First, compare what is actually disclosed.

JEOL reports a broad Scientific and Metrology Instruments segment. Bruker reports BSI BioSpin, which is closer to the magnetic-resonance question but still contains more than NMR. The rows below are useful boundaries, not like-for-like NMR economics.

Latest full-year segment context
MetricJEOLBruker
ListingTSE 6951NASDAQ BRKR
FY2025 company revenue¥179.4bn
Year ended Mar 2026		$3.4365bn
Year ended Dec 2025
Relevant disclosed segmentScientific & Metrology
Microscopy, NMR, MS and more		BSI BioSpin
Magnetic resonance, imaging, automation, services and more
Segment revenue¥116.3bn$878.8m
Segment operating margin11.2%11.9%
NMR-only revenueNot disclosedNot disclosed

Source: company full-year filings.15 Bruker BioSpin represented approximately 25.6% of Bruker’s 2025 revenue, calculated from reported figures. That is not the same as NMR’s share of Bruker.

03 / WHAT THE LAB SEES

The moat is a stack, not a magnet.

From the bench, changing vendor can reach far beyond replacing capital equipment. It may change probe compatibility, pulse programs, processing conventions, training materials, service relationships, standard operating procedures and the continuity of old-versus-new spectra. The resulting switching cost is our inference from the workflow—not a number reported by either company.

05Comparable historyArchived spectra, methods and baselines
04People & supportTraining, service engineers and local user knowledge
03Methods & softwareTopSpin or Delta, pulse sequences and processing
02Probes & accessoriesSample workflows and experiment-specific hardware
01Magnet & consoleThe visible capital asset

Three Japanese facilities, three different installed-base stories

A / OSAKA

A Bruker cluster

Osaka University’s Institute for Protein Research lists Bruker systems at 950, 800, 600, 500 and 400 MHz, alongside remote measurement capability.9

Signal: concentrated methods, training and support around one vendor.

B / RIKEN

A JEOL cluster

RIKEN’s Molecular Structure Characterization Unit lists multiple JEOL ECZ/ECA instruments from 400 to 600 MHz and dedicated support.10

Signal: JEOL is embedded in a major national research institution.

C / KYOTO

A mixed site

Kyoto University iCeMS lists both a Bruker AVANCE III 500 and a JEOL JNM-ECZ 600R system.11

Signal: coexistence is real; procurement is not always winner-takes-all.

LOCAL INFRASTRUCTURE

Both vendors teach the workflow in Japan.

JEOL’s current Japanese curriculum covers beginner, solution, solid-state, qNMR, multi-nuclear, probe and maintenance topics. Bruker’s 2026 Japan schedule includes multiple solution- and solid-state-NMR courses in Yokohama. Training is evidence of active ecosystem investment; it is not evidence that one vendor has a specific share.48

04 / TECHNOLOGY & STRATEGY

Bruker extends the frontier. JEOL connects the modalities.

BRUKER / HIGH FIELD

The flagship is a powerful signal—but a lumpy business.

Bruker’s GHz-class systems make the most visible technology statement. Yet its 2025 BioSpin revenue fell 3.0%, with fewer GHz-system sales—two versus four in 2024—among the reasons disclosed. A technology lead does not remove order timing.57

JEOL / CROSS-MODAL

The strategic pitch is a connected structural-biology toolkit.

JEOL’s medium-term plan pairs NMR and mass spectrometry with cryo-TEM and MicroED for drug discovery and structural analysis. That creates cross-selling logic, but execution has to be observed in life-science orders and margins—not assumed from the product map.1

05 / INVESTOR LENS

The latest quarter is a signal, not a verdict on NMR.

JEOL / Q1 FY2026

¥24.5bnnet sales / −39.1% YoY

JEOL reported a ¥2.0bn operating loss, citing revenue-recognition timing and tighter export controls among the factors. Management kept its full-year forecast unchanged. Because NMR is not separately disclosed, this quarter cannot be read as an NMR demand figure.2

BRUKER / Q2 2026

$838.5mrevenue / +2.8% organic

BSI bookings grew 10% organically with book-to-bill above one, while U.S. academic demand remained soft. Bruker also recorded a $134.9m non-cash goodwill impairment; non-GAAP operating margin was 14.1%. Both GAAP and adjusted views matter.6

What could falsify the thesis?

CompanyWatchWhy it matters
JEOLScientific & Metrology orders and marginTests whether life-science strategy becomes earnings rather than portfolio language.
JEOLSupport density outside JapanA Japanese service advantage does not automatically scale globally.
JEOLIndustrial-equipment mixHigh-margin semiconductor equipment can dominate the group-level earnings signal.
BrukerAcademic and government fundingHigh-end research systems have long, budget-sensitive sales cycles.
BrukerGHz order timing and BioSpin marginFlagship systems can make growth and mix unusually lumpy.
BrukerAcquisition integration and impairmentsPortfolio expansion only creates value if returns survive integration costs.

06 / VERDICT WITHOUT A RECOMMENDATION

Instrument preference is not an investment thesis.

For investors seeking the closer listed exposure to a global magnetic-resonance platform and the ultra-high-field frontier, Bruker is the more direct fit—but BioSpin was only about one quarter of 2025 group revenue and is not NMR-only.

For investors seeking a Japanese analytical-instrument platform whose earnings also connect strongly to electron microscopy and semiconductor equipment, JEOL is the more relevant frame—but an NMR comparison alone will not explain its profit engine.

High-field NMR signalBruker
Japan-based service signalBoth
Cross-modal Japan platformJEOL
Pure NMR exposureNeither

READER QUESTIONS / DIRECT ANSWERS

Questions investors ask about JEOL, Bruker and NMR.

01

Which company has the clearer position in ultra-high-field NMR?

Bruker has the clearer visible position at the ultra-high-field frontier. Its portfolio extends through GHz-class systems, and its 2025 annual report records two 1.2 GHz installations. That technical position does not remove order-timing or academic-funding risk.57

02

Is JEOL or Bruker a pure-play NMR investment?

Neither. JEOL reports NMR inside a broader Scientific and Metrology Instruments segment, while Bruker BioSpin also contains magnetic resonance, imaging, automation, services and data. Neither company discloses comparable NMR-only revenue.15

03

What do Japanese laboratory equipment lists reveal?

They show vendor-specific clusters and coexistence: Osaka University lists a Bruker cluster, RIKEN lists a JEOL cluster, and Kyoto University lists systems from both companies. This supports an installed-base and workflow analysis, not a national market-share estimate.91011

04

Why can switching NMR vendors be difficult?

The instrument sits inside a wider workflow of probes, pulse programs, processing software, training, service relationships, operating procedures and comparable historical spectra. The resulting switching cost is an editorial inference from the workflow and should not be mistaken for a figure reported by either company.48

日本語要約 / EDITOR’S SUMMARY

結論：装置の優劣だけで銘柄は選べない。

Brukerは超高磁場NMRで分かりやすい技術的ポジションを持ちます。一方、JEOLは日本国内の教育・保守基盤に加え、電子顕微鏡、MicroED、質量分析、NMRをつなぐ戦略があります。

ただし、両社ともNMR単独の売上高を開示していません。JEOLの収益は半導体関連装置の影響が大きく、BrukerのBioSpinにもNMR以外の事業が含まれます。したがって、投資家が追うべきなのは「どちらの装置が好きか」ではなく、関連セグメントの受注・利益率、大学研究費、保守・ソフトウェア収入、買収の統合状況です。

大学・研究機関の装置一覧は導入基盤の存在を示しますが、市場シェアを証明するものではありません。本稿では、根拠を確認できない具体的なシェア数字は採用していません。

DISCLOSURE / IMPORTANT

Position: The editor has disclosed a holding in Bruker. No compensation was received from either company for this report. This creates a potential bias, which readers should factor into their own work.

This publication is independent research and general information, not investment advice or a solicitation. Figures may be restated, translated or superseded. Verify all data with the original issuer materials.

SOURCES / PRIMARY MATERIALS

Evidence ledger

All sources below are issuer, product-maker or research-institution materials. Accessed August 24, 2026.

SUGGESTED CITATION

Japan Niche Lens Research Desk. “JEOL vs Bruker NMR: What Japanese Labs Reveal.” Japan Niche Lens, August 24, 2026. https://japannichelens.com/research/jeol-vs-bruker

  1. 01
    JEOL — FY2025 results and medium-term management plan

    Year ended March 2026; published May 15, 2026.

  2. 02
    JEOL — Q1 FY2026 financial results

    Quarter ended June 2026; published August 14, 2026.

  3. 03
  4. 04
    JEOL Japan — training curriculum

    Official course list, including solution, solid-state, qNMR and maintenance training.

  5. 05
    Bruker — 2025 annual report

    Company and BioSpin segment results for the year ended December 2025.

  6. 06
    Bruker — Q2 2026 financial results

    Quarter ended June 2026; published August 4, 2026.

  7. 07
    Bruker — GHz-class NMR systems

    Official high-field product overview.

  8. 08
    Bruker Japan — 2026 NMR training

    Official Japan course schedule for solution and solid-state NMR.

  9. 09
  10. 10
  11. 11
    Kyoto University iCeMS Analysis Center — equipment

    Official list showing both JEOL and Bruker systems.